Gilead Sciences (GILD) Competitors

Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Is AMGN or GILD more profitable?

Amgen has a net margin of 12.24% compared to Gilead Sciences' net margin of 1.67%. Amgen's return on equity of 176.32% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	12.24%	176.32%	11.71%
Gilead Sciences	1.67%	31.63%	10.38%

Which has more risk & volatility, AMGN or GILD?

Amgen has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.18, suggesting that its share price is 82% less volatile than the S&P 500.

Which has preferable valuation and earnings, AMGN or GILD?

Amgen has higher revenue and earnings than Gilead Sciences. Amgen is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$33.42B	4.87	$4.09B	$7.55	40.13
Gilead Sciences	$28.75B	4.77	$480M	$0.37	297.16

Do analysts recommend AMGN or GILD?

Amgen currently has a consensus target price of $314.09, indicating a potential upside of 3.66%. Gilead Sciences has a consensus target price of $102.08, indicating a potential downside of 7.16%. Given Amgen's higher possible upside, equities analysts plainly believe Amgen is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	10 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.46
Gilead Sciences	0 Sell rating(s)	11 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.72

Do institutionals and insiders believe in AMGN or GILD?

76.5% of Amgen shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 0.7% of Amgen shares are held by insiders. Comparatively, 0.2% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Does the MarketBeat Community believe in AMGN or GILD?

Gilead Sciences received 927 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 76.83% of users gave Gilead Sciences an outperform vote while only 72.03% of users gave Amgen an outperform vote.

Company	Underperform	Outperform
Amgen	Outperform Votes 1550 72.03%	Underperform Votes 602 27.97%
Gilead Sciences	Outperform Votes 2477 76.83%	Underperform Votes 747 23.17%

Does the media favor AMGN or GILD?

In the previous week, Gilead Sciences had 12 more articles in the media than Amgen. MarketBeat recorded 68 mentions for Gilead Sciences and 56 mentions for Amgen. Amgen's average media sentiment score of 1.57 beat Gilead Sciences' score of 1.27 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	51 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Gilead Sciences	48 Very Positive mention(s)	2 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is AMGN or GILD a better dividend stock?

Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.1%. Gilead Sciences pays an annual dividend of $3.08 per share and has a dividend yield of 2.8%. Amgen pays out 126.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences pays out 832.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Amgen beats Gilead Sciences on 14 of the 22 factors compared between the two stocks.